专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2001261577A CONTROL OF OXIDATION DECOMPOSITION OF PREPARATION FOR MEDICINE 失效
公开(公告)号：JP2001261577A
公开(公告)日：2001-09-26
申请号：JP2001068073
申请日：2001-03-12
申请人： PFIZER PROD INC
发明人： WANG HAI
IPC分类号： A61K9/00 , A61K47/02 , A61K47/12
摘要： PROBLEM TO BE SOLVED: To provide a method for producing a preparation for a medicine, capable of protecting one or plural active medicine components from oxidation decomposition and consequently facilitating a long-team preservation of the preparation. SOLUTION: This method controls oxidation decomposition of a preparation for a medicine containing at least one readily oxidizable active medicine component. The method comprises adding an iron (II) ion source preferably in a state of an excipient for a medicine in an amount to control oxidation to the preparation. The preparation for a medicine comprises at least one readily oxidizable active medicine component and an iron (II) ion source in an amount to control oxidation preferably in a state of an excipient for a medicine. The use of the iron (II) ion source in the preparation for a medicine as an antioxidant is provided.

2. 发明授权

US6423351B2 Inhibiting oxidative degradation of pharmaceutical formulations 失效
标题翻译：抑制药物制剂的氧化降解
公开(公告)号：US6423351B2
公开(公告)日：2002-07-23
申请号：US80345501
申请日：2001-03-09
申请人： PFIZER
发明人： WANG HAI
IPC分类号： A61K9/00 , A61K47/02 , A61K47/12 , A61K33/26 , A61K31/295 , A61K31/40 , A61K31/439
CPC分类号： A61K47/02 , Y10S424/06 , Y10S514/97 , Y10S514/973
摘要： The invention provides methods for inhibiting oxidative degradation of pharmaceutical formulations comprising at least one oxidation-susceptible active drug ingredient which methods comprise adding an oxidation-inhibiting amount of a ferrous ion source, preferably in the form of a pharmaceuticalexcipient, to the formulation.The invention further provides pharmaceutical formulations comprising at least one oxidation-susceptible active drug ingredient and an oxidation-inhibiting amount of a ferrous iron source, preferably in the form of a pharmaceuticalexcipient.The invention still further provides for the use of a ferrous ion source as an anti-oxidant in pharmaceutical formulations.
摘要翻译：本发明提供了抑制包含至少一种氧化敏感的活性药物成分的药物制剂的氧化降解的方法，所述方法包括向制剂中加入氧化抑制量的亚铁离子源，优选以药物释放剂的形式。还提供了包含至少一种氧化敏感的活性药物成分和氧化抑制量的亚铁源的药物制剂，优选以药物释放剂的形式。本发明还进一步提供了将亚铁离子源用作抗药物制剂中的氧化剂。

3. 发明申请

WO2005103003A3 PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS HIV-INTEGRASE INHIBITORS 审中-公开
标题翻译：吡咯啉衍生物及其作为HIV-整合酶抑制剂的用途
公开(公告)号：WO2005103003A3
公开(公告)日：2006-03-16
申请号：PCT/IB2005001029
申请日：2005-04-14
申请人： PFIZER , DRESS KLAUS RUPRECHT , HU QIYUE , JOHNSON TED WILLIAM , PLEWE MICHAEL BRUNO , TANIS STEVEN PAUL , WANG HAI , YANG ANLE , YIN CHUNFENG , ZHANG JUNHU
发明人： DRESS KLAUS RUPRECHT , HU QIYUE , JOHNSON TED WILLIAM , PLEWE MICHAEL BRUNO , TANIS STEVEN PAUL , WANG HAI , YANG ANLE , YIN CHUNFENG , ZHANG JUNHU
IPC分类号： A61K31/4745 , C07D213/00 , C07D471/02 , C07D471/04 , C07D519/00 , A61K31/435 , A61P31/18
CPC分类号： C07D471/04
摘要： The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus ("HIV") integrase enzyme.
摘要翻译：本发明涉及式（I）化合物及其药学上可接受的盐和溶剂合物，它们的合成及其作为人免疫缺陷病毒（“HIV”）整合酶的调节剂或抑制剂的用途。

4. 发明申请

WO2004039803A3 HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE 审中-公开
标题翻译： HIV-INTEGRASE INHIBITORS，PHARMACEUTICAL COMPOSITIONS及其使用方法
公开(公告)号：WO2004039803A3
公开(公告)日：2004-09-16
申请号：PCT/IB0304735
申请日：2003-10-27
申请人： PFIZER , HU QIYUE , KUKI ATSUO , NOWLIN DAWN MARIE , PLEWE MICHAEL BRUNO , WANG HAI , ZHANG JUNHU
发明人： HU QIYUE , KUKI ATSUO , NOWLIN DAWN MARIE , PLEWE MICHAEL BRUNO , WANG HAI , ZHANG JUNHU
IPC分类号： A61K31/435 , A61P31/18 , C07D471/04 , C07D471/12 , C07D471/14
CPC分类号： C07D471/04 , C07D471/12 , C07D471/14
摘要： Bicyclic hydroxamate compounds represented by the Formula I are described. The bicyclic hydroxamate compounds and compositions containing those compounds may be used to inhibit or modulate an enzyme activity of HIV Integrase and to treat HIV mediated diseases and conditions.
摘要翻译：描述由式I表示的双环氧肟酸盐化合物。双环异羟肟酸酯化合物和含有这些化合物的组合物可用于抑制或调节HIV整合酶的酶活性并治疗HIV介导的疾病和病症。

5. 发明专利

UY28048A1 INHIBIDORES DE HIV-INTEGRASA,COMPOSICIONES FARMACÉUTICAS Y MÉTODOS PARA SU USO 未知
公开(公告)号：UY28048A1
公开(公告)日：2004-05-31
申请号：UY28048
申请日：2003-10-28
申请人： PFIZER
发明人： HU QIYUE , KUKI ATSUO , NOWLIN DAWN MARIE , PLEWE MICHAEL BRUNO , WANG HAI , ZHANG JUNHU
IPC分类号： A61K31/435 , A61P31/18 , C07D471/04 , C07D471/12 , C07D471/14 , A61P31/00 , C07D209/00 , C07D221/00 , C07D233/00 , C07D235/00 , C07D249/00 , C07D471/02 , C07D487/00
摘要： Se describen compuestos de hidroxamatos bicíclicos representados por la fórmula I: Los compuestos de hidroxamato bicíclicos y las composiciones que contienen estos compuestos pueden ser usados para inhibir o modular una actividad enzimática de HIV- integrasa y para tratar enfermedades y estados mediados por HIV.

6. 发明专利

AU2003269421A8 Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use 未知
公开(公告)号：AU2003269421A8
公开(公告)日：2004-05-25
申请号：AU2003269421
申请日：2003-10-27
申请人： PFIZER
发明人： PLEWE MICHAEL BRUNO , HU QIYUE , ZHANG JUNHU , NOWLIN DAWN MARIE , WANG HAI , KUKI ATSUO
IPC分类号： A61K31/435 , A61P31/18 , C07D471/04 , C07D471/12 , C07D471/14 , C07D221/00 , C07D209/00 , C07D235/00
摘要： Bicyclic hydroxamate compounds represented by the Formula I: are described. The bicyclic hydroxamate compounds and compositions containing those compounds may be used to inhibit or modulate an enzyme activity of HIV Integrase and to treat HIV mediated diseases and conditions.

7. 发明专利

NL1024676A1 HIV integrase-remmers, farmaceutische preparaten en methoden voor het gebruik daarvan. 未知
公开(公告)号：NL1024676A1
公开(公告)日：2004-05-06
申请号：NL1024676
申请日：2003-10-31
申请人： PFIZER
发明人： HU QIYUE , KUKI ATSUO , NOWLIN DAWN MARIE , PLEWE MICHAEL BRUNO , WANG HAI , ZHANG JUNHU
IPC分类号： A61K31/435 , A61P31/18 , C07D471/04 , C07D471/12 , C07D471/14

8. 发明专利

MXPA06012449A INHIBIDORES DE LA ENZIMA INTEGRASA DE VIH. 未知
公开(公告)号：MXPA06012449A
公开(公告)日：2007-01-17
申请号：MXPA06012449
申请日：2005-04-14
申请人： PFIZER
发明人： WANG HAI , PLEWE MICHAEL BRUNO , ZHANG JUNHU , TANIS STEVEN PAUL , DRESS KLAUS RUPRECHT , HU QIYUE , JOHNSON TED WILLIAM , YANG ANLE , YIN CHUNFENG
IPC分类号： A61K31/435 , A61K31/4745 , A61P31/18 , C07D213/00 , C07D471/02 , C07D471/04 , C07D519/00
摘要： La presente invencion se refiere a compuestos de formula (I), y a sales farmaceuticamente aceptables y solvatos de los mismos, a su sintesis y a su uso como moduladores o inhibidores de la enzima integrasa del virus de la inmunodeficiencia humana ("VIH") (ver formula (I)).

9. 发明专利

CA2564356A1 PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS HIV-INTEGRASE INHIBITORS 未知
公开(公告)号：CA2564356A1
公开(公告)日：2005-11-03
申请号：CA2564356
申请日：2005-04-14
申请人： PFIZER INC A CORP ORGANIZED UN
发明人： YANG ANLE , YIN CHUNFENG , JOHNSON TED WILLIAM , PLEWE MICHAEL BRUNO , ZHANG JUNHU , DRESS KLAUS RUPRECHT , HU QIYUE , TANIS STEVEN PAUL , WANG HAI
IPC分类号： C07D471/04 , A61K31/435 , A61K31/4745 , A61P31/18 , C07D213/00 , C07D471/02 , C07D519/00
摘要： The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (~HIV~) integrase enzyme.

10. 发明专利

CA2513141A1 HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE 未知
公开(公告)号：CA2513141A1
公开(公告)日：2004-08-12
申请号：CA2513141
申请日：2004-01-23
申请人： PFIZER LTD
发明人： KUKI ATSUO , ZHANG JUNHU , WANG HAI , PLEWE MICHAEL BRUNO , LI XINQIANG
IPC分类号： A61P31/18 , C07D471/04 , A61K31/437
摘要： Beta-carboline hydroxamic acid compounds represented by formula (I) and formula (lb) are described, wherein: R1, R2, R3, R4, R5, and R6 are independently selected from hydrogen, halogen, C1_C6 alkyl, aikoxy C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -ORc, -NO2, and -N(Rc)2, each Rc is Independently selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, and C2-Ca alkynyl; R7 Is C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, all of which ar e optionally substituted by one or more substituents independently selected fr om halogen, C1-C6 alkyl, C2-C6 alkenyl; C2-C6 alkynyl, aryl, cycloalkyl, heterocycioalkyl, and heteroaryl, wherein said aryl, cydoalkyi, and heterocycloalkyl are optionally substituted with one or more substituents independently selected from halogen, C1-C6 alkyl, C2-C6 alkenyl, and C2-C6 alkynyl; R8 and R9 are independently selected from hydrogen, C1-C6 alkyl, C2 - C6 alkenyl, and C2-C6 aikynyl, wherein said alkyl, alkenyl, and alkynyl are optionally substituted with one or more substituents independently selected from halogen, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl group, wherein said aryl, cycloalkyl, and heterocycloalkyl are optionally substitut ed with one or more substituents independently selected from halogen, C1-C6 alkyl, C2-C6 alkenyl, and C2-C6 alkynyl. The beta-carboline hydroxamic acid compounds and compositions containing those compounds may be used to inhibit or modulate the activity of HIV integrase enzyme and to treat HIV integrase- mediated diseases and conditions.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式